
L.VAD Technology Inc (AKA: CardioPlus Inc~ViaDerm LLC) Profile last edited on: 2/7/2023
CAGE: 6LLV1
UEI: W1LMB8B7QS45
Business Identifier: interruptible, heart assist devices for treatment of heart failure Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
46701 North Commerce Center Drive
Plymouth, MI 48170
Plymouth, MI 48170
(734) 233-3985 |
info@viadermllc.com |
www.lvadtech.com |
Location: Single
Congr. District: 06
County: Wayne
Congr. District: 06
County: Wayne
Public Profile
L VAD Technology, Inc.is a firm company dedicated to the research and development of mechanical systems for treating heart failure. The company has developed the CardioPlus Device. CardioPlus functions like the intraaortic balloon pump, for 30 years, the gold standard for hospital treatment of acute heart failure. The CardioPlus is more powerful than the balloon pump and allows the CHF patient to live at home and resume many normal activities. The device contains only 2 implanted components: 1) A one ounce, 5", 60cc pump implanted in the aorta, has no valves, inflates and deflates using room air. and 2) A proprietary connector, precovered with patients own skin cells to promote stability, allowing detachment from the drive unit. The drive unit is external, detachable, and readily replaceable. One version is battery-powered, weighs 5 pounds and is worn in a vest. The other looks like carry-on luggage, has wheels and uses house current. CardioPlus simple, elegant design has demonstrated it can: Improve advanced heart failure patients by at least one functional class, relieve symptons of CHF, reduce or eliminate need for Inotropic medications. Be turned on and off with a simple switch without risk of emboli, without use of anticoagulants.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2014 | 2 | NIH | $1,764,299 | |
Project Title: Novel, Long-Term Percutaneous Access Device for Chronic Therapy | ||||
2005 | 2 | NIH | $1,086,566 | |
Project Title: Long-Term Percutaneous Access Device for Home Therapies | ||||
1990 | 2 | NIH | $550,000 | |
Project Title: Precutaneous access device for peritoneal dialysis | ||||
1988 | 2 | NIH | $550,000 | |
Project Title: Mechanical auxiliary ventricle | ||||
1984 | 1 | NIH | $50,000 | |
Project Title: Percutaneous system for energy transmission |
Key People / Management
Adrian Kantrowitz -- President
Paul S Freed -- Vice President
Adrian Kantrowitz
Daniel Wadsworth
Paul S Freed -- Vice President
Adrian Kantrowitz
Daniel Wadsworth
Company News
There are no news available.